Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

Fig. 2

PFS of the different EOT CD4 levels and according to IGHV mutational status in the whole population. (A) PFS curves according to EOT CD4 status in the whole population (p = 0.0016). (B) PFS curves according to EOT CD4 status in patients with IGHV-unmutated status (p < 0.0001) (C) PFS curves according to EOT CD4 status in patients with mutated IGHV (p = 0.0576)

Back to article page